Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion

Takeda, Satoru; Munakata, Ryo; Abe, Shinji; Mii, Seiji; Suzuki, Manabu; Kashiwada, Takeru; Azuma, Arata; Yamamoto, Takeshi; Gemma, Akihiko; Tanaka, Keiji

doi:10.1007/s00134-010-1830-8

Cited by 31 publications

(28 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The polymyxin B-immobilized fiber column, first introduced in Japan in 1994, is an extracorporeal device using polymyxin-B fixed to h-chloroacetamide-methyl polystyrene-derived fibers, which can remove circulating endotoxin and reduce various cytokines through direct hemoperfusion (Takeda et al, 2010). In a 16-yearold girl with severe H1N1pdm09 influenza who did not initially respond to inhalation of dry powder NAI zanamivir 10 mg twice-daily, hypercytokinemia (elevated IL-6, IL-8, IFN-c, and high-mobility group box-1) was successfully reduced with column hemoperfusion, resulting in a favorable clinical outcome (Takeda et al, 2010).…”

Section: Polymyxin B-immobilized Fiber Column Hemoperfusionmentioning

confidence: 99%

Adjunctive therapies and immunomodulatory agents in the management of severe influenza

2013

View full text Add to dashboard Cite

In addition to neuraminidase inhibitors and other drugs that directly target viral replication, a number of adjunctive and immunomodulatory therapies are currently under evaluation for the treatment of influenza. These novel treatments, which focus either on pathophysiological aspects of influenza virus infection or the neutralization of virus with antibodies, are the subject of this review. Cytokine dysregulation has been observed in patients with severe influenza, such as avian influenza A (H5N1) and pandemic 2009 influenza A (H1N1pdm09) virus infections, but the role of immunomodulatory therapy is unclear, due to lack of data from randomized controlled trials (RCTs). Convalescent plasma appears to be useful as an adjunctive therapy for the treatment of H5N1 and H1N1pdm09 infections. Until lately, data interpretation was limited to case reports and studies of non-randomized design, but a recent RCT found that patients with severe influenza A (H1N1pdm09) who were treated with hyperimmune immunoglobulin from persons who had survived the same disease had a lower peak viral load and lower mortality than controls, providing treatment was begun within 5 days of symptom onset. The efficacy of agents with potential immunomodulating effects, including intravenous immunoglobulin, N-acetylcysteine, acute use of statins, macrolides, peroxisome proliferator-activated receptors agonists, celecoxib and mesalazine, and the role of plasmapheresis and hemoperfusion as rescue therapy, deserve more investigation and where feasible, studies by RCTs. Prospective observational studies have shown that systemic corticosteroids increase morbidity (e.g., secondary infections) and mortality in H1N1pdm09 influenza. This article forms part of a symposium in Antiviral Research on "Treatment of influenza: targeting the virus or the host."

show abstract

Section: Polymyxin B-immobilized Fiber Column Hemoperfusionmentioning

confidence: 99%

Adjunctive therapies and immunomodulatory agents in the management of severe influenza

2013

View full text Add to dashboard Cite

show abstract

“…Hypercytokinemia resolved promptly and the reduced a/APO 2 improved significantly after 4 h active treatment. These favorable changes may have been attributable to the active treatment based on previous reports . Decreased levels of not only endotoxin, but also various mediators including IL‐6, IL‐8, IL‐10, tumor necrosis factor‐α, and interferon‐γ are reported in patients treated with PMX‐DHP .…”

Section: Discussionmentioning

confidence: 66%

Polymyxin B‐immobilized fiber column direct hemoperfusion and continuous hemodiafiltration in premature neonates with systemic inflammatory response syndrome

Maede

Ibara

Tokuhisa

et al. 2016

Pediatrics International

View full text Add to dashboard Cite

show abstract

“…On the other hand, current World Health Organization guidance does not recommend the use of corticosteroid for severe or progressive infection with pandemic H1N1 2009. However, it does describe the occasional usage of corticosteroid as an adjunctive therapy for the treatment of ARDS in severe influenza virus infection due to their potentially immunomodulatory properties for virus-mediated cytokine dysregulation (13,18). In ARDS patients with pandemic H1N1 influenza, corticosteroid treatment was well tolerated and it mostly promised substantial improvement in ALI, multiorgan dysfunction scores and low hospital mortality (4).…”

Section: Discussionmentioning

confidence: 99%

A Case of Successful Treatment with Polymyxin B-immobilized Fiber Column Direct Hemoperfusion in Acute Respiratory Distress Syndrome after Influenza A Infection

et al. 2011

View full text Add to dashboard Cite

We report a case of acute respiratory distress syndrome (ARDS) after influenza A infection who was successfully treated with combined treatment including direct hemoperfusion with polymyxin B-immobilized fiber (PMX-DHP) column. A 56-year-old Japanese man was admitted to our hospital in January 2010 because of progressive dyspnea, hypoxemia, fever and bilateral diffuse infiltration on chest radiograph after pandemic influenza A infection. His chest computed tomography showed diffuse and patchy bilateral ground-glass opacities, and we diagnosed ARDS after influenza A infection. The patient was successfully treated with PMX-DHP in addition to the treatment with oseltamivir, corticosteroid, sivelestat and antibiotics with mechanical ventilation, and the patient recovered with only minor pulmonary fibrotic change. Although the efficacy of PMX-DHP treatment in patients with acute lung injury (ALI)/ARDS after influenza virus infection is not well established, this treatment could be a possible therapeutic modality in treating the patients with this disease.

show abstract

Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion

Cited by 31 publications

References 5 publications

Adjunctive therapies and immunomodulatory agents in the management of severe influenza

Adjunctive therapies and immunomodulatory agents in the management of severe influenza

Polymyxin B‐immobilized fiber column direct hemoperfusion and continuous hemodiafiltration in premature neonates with systemic inflammatory response syndrome

A Case of Successful Treatment with Polymyxin B-immobilized Fiber Column Direct Hemoperfusion in Acute Respiratory Distress Syndrome after Influenza A Infection

Contact Info

Product

Resources

About